Thursday, March 04, 2010 12:19:40 PM
I have been talking and looking for this financing for six months. I don't want to rain on your parade, but we are in for some dilution like I had expected. I expected the Outstanding shares to increase to 105 million, looks like 107 million, if the warrants are not purchased. Why do you think no one is buying today? I love Mhan Opportunity's for a spike, but I will try to get the best price and .065 is not it. Mhan sold 102 units, each unit consisting of 357,143 of common stock and 535,714 to purchase warrants. I was expecting outstanding shares to increase to 105 million, this seems much higher. That is 36,428,586 million shares of common stock and 54,642,828 million common stock issued by the purchase of warrants at .08. Please correct me if I am wrong. Any thoughts? If you take 2.55 million in proceeds with the common stock of 36,428,586 it gives you .07pps. 2,550,000/36,428,586= .07pps. I will be contacting IR today, but I am expecting dilution and the Hedrin and Ast trail are not close to being underway. I am looking for massive dilution and I am sticking with it. We do have a winner here fellas in the long run, we need to beat them at there own game.
Recent TGTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 08:33:42 PM
- TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million • GlobeNewswire Inc. • 03/19/2026 11:30:00 AM
- Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis • GlobeNewswire Inc. • 03/09/2026 11:30:00 AM
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting • GlobeNewswire Inc. • 03/06/2026 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2026 10:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:08:34 PM
- TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance • GlobeNewswire Inc. • 02/26/2026 12:00:00 PM
- TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis • GlobeNewswire Inc. • 02/17/2026 12:30:00 PM
- TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis • GlobeNewswire Inc. • 02/08/2026 09:17:55 PM
- TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum • GlobeNewswire Inc. • 02/06/2026 12:30:00 PM
- TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum • GlobeNewswire Inc. • 01/27/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2026 09:27:48 PM
- TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones • GlobeNewswire Inc. • 01/13/2026 09:25:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:16:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:15:33 PM
- TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/07/2026 12:30:00 PM
- TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference • GlobeNewswire Inc. • 11/28/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/25/2025 10:31:57 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/24/2025 09:04:15 PM
- TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies • GlobeNewswire Inc. • 11/19/2025 01:30:00 PM
- TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit • GlobeNewswire Inc. • 11/10/2025 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/07/2025 10:01:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/05/2025 09:31:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2025 12:34:54 PM
